Top Markets
Coin of the day
Agile Therapeutics, Inc. Agile Therapeutics, Inc.

Agile Therapeutics, Inc.

AGRX
주식 순위 #38231
Agile Therapeutics, Inc. operates as a women's healthcare enterprise dedicated... Agile Therapeutics, Inc. operates as a women's healthcare enterprise dedicated to the research, development, and market introduction of prescription contraception in the United States. Its flagship product is Twirla (also known by its development code, AG200-15), a combined hormonal contraceptive delivered through a patch applied once weekly. The company is also progressing with several pipeline innovations, including variations of Twirla and other new products: AG200-15 Extended Regimen (ER): A regimen designed to limit a woman to four withdrawal bleeding occurrences annually. AG200-15 smaller patch (SmP): This iteration aims for shorter, lighter withdrawal bleeds and potentially enhanced contraceptive efficacy. AG200-15 ER SmP: A combined regimen that allows for an extended contraceptive cycle while simultaneously providing fewer, lighter annual bleeding episodes. P-Patch: A contraceptive patch containing only progestin, specifically intended for women who cannot or choose not to use estrogen. Agile Therapeutics, Inc. was founded in 1997 and is based in Princeton, New Jersey.
주가
$1.51
마지막 동기화: 2024-08-26
시가총액
$1.12M
변동 (1일)
0.00%
변동 (1년)
0.00%
국가
US
거래 Agile Therapeutics, Inc. (AGRX)

카테고리

Agile Therapeutics, Inc. (AGRX)의 발행 주식 수
June 2024 기준 발행 주식 수: 6.86M
Agile Therapeutics, Inc.의 최신 재무 보고서와 주가에 따르면 현재 발행 주식 수는 6.86M입니다. December 2022 말 기준 회사는 432.22K주를 발행했습니다. 발행 주식 수는 일반적으로 주식 분할이나 자사주 매입에 의해 영향을 받습니다.
Agile Therapeutics, Inc. (AGRX)의 발행 주식 수 기록 (2012 ~ 2026)
매년 말 기준 발행 주식 수
연도 발행 주식 수 변화
2026 (TTM) 6.86M 217.90%
2023 2.16M 398.99%
2022 432.22K 35,520.10%
2021 1.21K -97.13%
2020 42.34K 71.31%
2019 24.72K 44.06%
2018 17.16K 10.90%
2017 15.47K 9.44%
2016 14.14K 28.42%
2015 11.01K 93.22%
2014 5.70K 26.21%
2013 4.51K 0.00%
2012 4.51K 0.00%
유사 기업 또는 경쟁사의 발행 주식 수